Bagril Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -52.24%
- Profit Growth -98.68%
- Ebitda 94.53%
- Net Worth 0.56%
- Total Assets 107.37%
About Bagril Biotech
Bagril Biotech Private Limited (BBPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 April 2020 (Four years and ten months 16 days old ). Its registered office is in Gurugram, Haryana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Krishan Kumar, Subhash Chander, Himanshu Chaudhary, and One other member serve as directors at the Company.
Company Details
- Location
Gurugram, Haryana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999HR2020PTC086049
- Company No.
086049
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Apr 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Bagril Biotech?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krishan Kumar  | Additional Director | 07-Aug-2024 | Current |
| Subhash Chander | Additional Director | 07-Aug-2024 | Current |
| Himanshu Chaudhary | Director | 08-Apr-2020 | Current |
| Saroj Devi | Director | 08-Apr-2020 | Current |
Financial Performance of Bagril Biotech.
Bagril Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 52.24% decrease. The company also saw a substantial fall in profitability, with a 98.68% decrease in profit. The company's net worth moved up by a moderate rise of 0.56%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bagril Biotech?
Unlock access to Bagril Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bagril Biotech?
Bagril Biotech has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bagril Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bagril Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.